A QSAR and Pharmacophore Survey on Tyrosine Kinase Inhibitors with Effect on Epidermal Growth Factor Receptor

References

1. XuM.J. JohnsonD.E. GrandisJ.R. EGFR-targeted therapies in the post-genomic era.Cancer Metastasis Rev.201736346347310.1007/s10555‑017‑9687‑8 28866730
   [Google Scholar]
2. GrantS.K. Therapeutic protein kinase inhibitors.Cell. Mol. Life Sci.20096671163117710.1007/s00018‑008‑8539‑7 19011754
   [Google Scholar]
3. NobleM.E.M. EndicottJ.A. JohnsonL.N. Protein kinase inhibitors: Insights into drug design from structure.Science200430356651800180510.1126/science.1095920 15031492
   [Google Scholar]
4. AroraA. ScholarE.M. Role of tyrosine kinase inhibitors in cancer therapy.J. Pharmacol. Exp. Ther.2005315397197910.1124/jpet.105.084145 16002463
   [Google Scholar]
5. MadhusudanS. GanesanT.S. Tyrosine kinase inhibitors in cancer therapy.Clin. Biochem.200437761863510.1016/j.clinbiochem.2004.05.006 15234243
   [Google Scholar]
6. CohenM.H. WilliamsG.A. SridharaR. ChenG. PazdurR. FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets.Oncologist20038430330610.1634/theoncologist.8‑4‑303 12897327
   [Google Scholar]
7. IrmerD. FunkJ.O. BlaukatA. EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy.Oncogene200726395693570110.1038/sj.onc.1210383 17353898
   [Google Scholar]
8. ZhaoY. BilalM. RazaA. Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer.Int. J. Biol. Macromol.2021168223710.1016/j.ijbiomac.2020.12.009 33290765
   [Google Scholar]
9. RoskoskiR.Jr Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.Pharmacol. Res.202015210460910.1016/j.phrs.2019.104609 31862477
   [Google Scholar]
10. SabeV.T. NtombelaT. JhambaL.A. Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review.Eur. J. Med. Chem.202122411370510.1016/j.ejmech.2021.113705 34303871
    [Google Scholar]
11. DixonS.L. SmondyrevA.M. KnollE.H. RaoS.N. ShawD.E. FriesnerR.A. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.J. Comput. Aided Mol. Des.20062010-1164767110.1007/s10822‑006‑9087‑6 17124629
    [Google Scholar]
12. Hajiagha BozorgiA. ZarghiA. Search for the pharmacophore of histone deacetylase inhibitors using pharmacophore query and docking study.Iran. J. Pharm. Res.201413411651172 25587304
    [Google Scholar]
13. Hajiagha BozorgiA. GhomiH. Tabatabaei, Jouyban A. QSAR and pharmacophore studies of telomerase inhibitors.Medicinal Chemistry Resreash20116853866
    [Google Scholar]
14. RoyK. KarS. Das RN. Statistical methods in QSAR/QSPR.In: A primer on QSAR/QSPR modeling. Springer2015375910.1007/978‑3‑319‑17281‑1_2
    [Google Scholar]
15. GonzálezM. TeránC. Saíz-Urra L. Teijeira M. Variable selection methods in QSAR: An overview.Curr. Top. Med. Chem.20088181606162710.2174/156802608786786552 19075770
    [Google Scholar]
16. YooC. ShahlaeiM. The applications of PCA in QSAR studies: A case study on CCR5 antagonists.Chem. Biol. Drug Des.201891113715210.1111/cbdd.13064 28656625
    [Google Scholar]
17. GoodarziM. DejaegherB. HeydenY.V. Feature selection methods in QSAR studies.J. AOAC Int.201295363665110.5740/jaoacint.SGE_Goodarzi 22816254
    [Google Scholar]
18. KaregowdaA.G. ManjunathA.S. JayaramM.A. Feature subset selection problem using wrapper approach in supervised learning.Int. J. Comput. Appl.201017131710.5120/169‑295
    [Google Scholar]
19. https://www.chemcomp.com/Available from: https://www.chemcomp.com/index.htm
20. MosayebniaM. Hajiagha BozorgiA. RezaeianpourM. KobarfardF. In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.J. Biomol. Struct. Dyn.202240146569658610.1080/07391102.2021.1886991 33599180
    [Google Scholar]
21. LiangJ-w. Discovery of ABCG2/VEGFR2 dual-target inhibitor with anti-drug resistance activity based on the ATP binding site.Research Square202010.21203/rs.3.rs‑127221/v1
    [Google Scholar]
22. ProsserK.E. StokesR.W. CohenS.M. Evaluation of 3-dimensionality in approved and experimental drug space.ACS Med. Chem. Lett.20201161292129810.1021/acsmedchemlett.0c00121 32551014
    [Google Scholar]
23. Available from:https://www.nlm.nih.gov/nichsr/stats_tutorial/section2/mod8_sd.html#:~:text=A%20standard%20deviation%20
24. FatemehKeramatnia AliShayanfar HajiaghaBozorgi A. Marjan Mottaghi &. AbolghasemJouyban Prediction of drug solubility data in polyethylene glycols + water mixtures at various temperatures.Lat. Am. J. Pharm.201534816141621
    [Google Scholar]
25. JawarkarR.D. SharmaP. JainN. QSAR, molecular docking, md simulation and mmgbsa calculations approaches to recognize concealed pharmacophoric features requisite for the optimization of alk tyrosine kinase inhibitors as anticancer leads.Molecules20222715495110.3390/molecules27154951 35956900
    [Google Scholar]
26. SunX. ChenL. LiY. Structure-based ensemble-QSAR model: A novel approach to the study of the EGFR tyrosine kinase and its inhibitors.Acta Pharmacol. Sin.201435230131010.1038/aps.2013.148 24335842
    [Google Scholar]
27. A QSAR study on a series of indolin-2-ones acting as non-receptor src tyrosine kinase inhibitors.Lett. Drug Des. Discov.2011810[918 - 925].
    [Google Scholar]
28. AbdulilahE.C.E. E-pharmacophore mapping combined with virtual screening and molecular docking to identify potent and selective inhibitors of p90 ribosomal s6 kinase (rsk).Turk J Pharm Sci2016132241248
    [Google Scholar]
29. ChangY-S. WangB-C. YangL-L. Pharmacophore modeling of tyrosine kinase inhibitors: 4-anilinoquinazoline derivatives.J. Chin. Chem. Soc.2010574B91692410.1002/jccs.201000127
    [Google Scholar]